Vertex Pharmaceuticals stock heads into Q3 results after close
Published on 11/02/2026 at 12:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch
- Vertex will publish third-quarter 2026 results after the US market close on Monday.
- The earnings call is scheduled for 4:30 p.m. Eastern Time and will be webcast.
- The company is expanding beyond cystic fibrosis into areas including acute pain, kidney disease and acromegaly.
Vertex Pharmaceuticals is heading into a scheduled earnings catalyst on Monday, November 2, 2026. The biotechnology company said in an October 7 release that it will publish its third-quarter results after financial markets close in the United States.
The company will host an earnings call and webcast at 4:30 p.m. Eastern Time. Investors can access the webcast through the investor section of Vertex's website, while an archived version will be available afterward. The schedule was announced by Vertex investor relations.
Expansion beyond cystic fibrosis
Vertex says its approved medicines cover cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly. The portfolio gives the quarterly report importance beyond the established cystic-fibrosis franchise, as investors assess the company's ability to build additional sources of growth.
The company also lists investigational programs in IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, Cushing's syndrome, polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. The breadth of the pipeline leaves product progress and launch execution as key topics for the call.
Vertex Pharmaceuticals stock before results
Vertex Pharmaceuticals stock traded at 497.98 euros on Lang & Schwarz at 12:35 CET on Monday, November 2, 2026. Investors can follow the real-time quote of Vertex Pharmaceuticals stock while waiting for the release.
Vertex Pharmaceuticals
- ISIN: US92532F1003
- Ticker: VRTX
- Trading venue: Lang & Schwarz
- Price: 497.98 euros at 12:35 CET on November 2, 2026
- Next event: Third-quarter 2026 results after the US market close on November 2, 2026
The broader US equity market remains the relevant backdrop for the stock, with current market reports available through the S&P 500 market page.
Further updates will follow on the more news and analyses on Vertex Pharmaceuticals stock page.
